NASDAQ:RVMD

Revolution Medicines Stock Insider Trading

Healthcare > Biotechnology

Buy RVMD

*Your capital is at risk

$169.51

+3.70 (+2.23%)

At Close: Jun 23, 2026

Revolution Medicines Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -63.20. In total, the insiders bought 1.35M and sold 367.51K RVMD shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-63.20
● Buy	1.35M shares
● Sell	367.51K shares
59% Buy Activity Weak Negative Correlation
Sell Signal Medium Confidence Jun 15, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -63.2. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 18, 2026 Buy	Common Stock A-Award	Horning Sandra Director	Director	1 191 Value: $194.1K
Jun 18, 2026 Buy	Stock Option (Right to Buy) A-Award	Horning Sandra Director	Director	3 127 Value: $509.7K
Jun 18, 2026 Buy	Common Stock A-Award	Clyburn Frank Director	Director	1 191 Value: $194.1K
Jun 18, 2026 Buy	Stock Option (Right to Buy) A-Award	Clyburn Frank Director	Director	3 127 Value: $509.7K
Jun 18, 2026 Buy	Common Stock A-Award	Patel Sushil Director	Director	1 191 Value: $194.1K
Jun 18, 2026 Buy	Stock Option (Right to Buy) A-Award	Patel Sushil Director	Director	3 127 Value: $509.7K
Jun 18, 2026 Buy	Common Stock A-Award	Borellini Flavia Director	Director	1 191 Value: $194.1K
Jun 18, 2026 Buy	Stock Option (Right to Buy) A-Award	Borellini Flavia Director	Director	3 127 Value: $509.7K
Jun 18, 2026 Buy	Common Stock A-Award	Anderson Elizabeth M Director	Director	1 191 Value: $194.1K
Jun 18, 2026 Buy	Common Stock A-Award	Borisy Alexis Director	Director	1 191 Value: $194.1K
Jun 18, 2026 Buy	Common Stock A-Award	Kim Lorence H. Director	Director	1 191 Value: $194.1K
Jun 18, 2026 Buy	Stock Option (Right to Buy) A-Award	Kim Lorence H. Director	Director	3 127 Value: $509.7K
Jun 18, 2026 Buy	Stock Option (Right to Buy) A-Award	Borisy Alexis Director	Director	3 127 Value: $509.7K
Jun 18, 2026 Buy	Stock Option (Right to Buy) A-Award	Anderson Elizabeth M Director	Director	3 127 Value: $509.7K
Jun 17, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Horn Margaret A Chief Operating Officer	C-Suite Officer	3 302 Value: $98.4K
Jun 17, 2026 Buy	Common Stock M-Exempt	Horn Margaret A Chief Operating Officer	C-Suite Officer	573 Value: $23.3K
Jun 17, 2026 Sell	Common Stock S-Sale	Horn Margaret A Chief Operating Officer	C-Suite Officer	29 600 Value: $4.74M
Jun 17, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Horn Margaret A Chief Operating Officer	C-Suite Officer	25 725 Value: $681.7K
Jun 17, 2026 Buy	Common Stock M-Exempt	Horn Margaret A Chief Operating Officer	C-Suite Officer	3 302 Value: $98.4K
Jun 17, 2026 Buy	Common Stock M-Exempt	Horn Margaret A Chief Operating Officer	C-Suite Officer	25 725 Value: $681.7K
Jun 17, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Horn Margaret A Chief Operating Officer	C-Suite Officer	573 Value: $23.3K
Jun 16, 2026 Sell	Common Stock S-Sale	Mancini Anthony See Remarks	Officer	4 615 Value: $720.5K
Jun 16, 2026 Sell	Common Stock S-Sale	Goldsmith Mark A See Remarks	Officer	10 020 Value: $1.56M
Jun 16, 2026 Sell	Common Stock S-Sale	Cislini Jeff General Counsel	Officer	2 157 Value: $336.7K
Jun 16, 2026 Sell	Common Stock S-Sale	Anders Jack Chief Financial Officer	C-Suite Officer	2 722 Value: $425.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT REVOLUTION MEDICINES INC.

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells...

Read Full Profile Here